Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients with Waldenström Macroglobulinemia By webmaster / June 16, 2025
Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory CLL: Updated Findings From an Ongoing Phase 1a Study By webmaster / June 16, 2025
Identification of Selective, Orally Bioavailable Aurora A Degraders for Treatment of Pediatric and Adult Cancers By webmaster / April 29, 2025
DEL-AI: Proteome-Wide In Silico Screening of Multi-Billion Compound Libraries Using Machine Learning Foundation Models By webmaster / April 28, 2025
NRX-0305: A Pan-Mutant BRAF Degrader with Broad Preclinical Efficacy, Brain Penetrance, and Synergistic Potential with MEK Inhibition Across Class 1/2/3 BRAF-mutant Cancers By webmaster / April 25, 2025
Bexobrutideg (NX-5948) is a CNS-Penetrant Catalytic Bruton’s Tyrosine Kinase (BTK) Degrader that Breaks Established Design Rules for CNS Drugs By webmaster / April 25, 2025
NX-5948 and NX-2127 Potently Degrade a Broad Array of Clinically-Relevant BTK Mutants That Display Resistance to Inhibitors and Other BTK Degraders By webmaster / March 25, 2025
IRAK4 Degrader GS-6791 Inhibits TLR And IL-1R-Driven Inflammatory Signaling, And Ameliorates Disease In A Preclinical Arthritis Model By aterrado@waterhousebrands.com / January 7, 2025
An Orally Bioavailable, Brain Penetrant, Pan-Mutant BRAF Degrader For The Treatment Of Primary And Inhibitor-Resistant Solid Tumors By aterrado@waterhousebrands.com / January 7, 2025
